Lupin strengthens European eye-care platform through VISUfarma

The completed acquisition gives Lupin a larger branded ophthalmology portfolio and a stronger commercial footprint across key European markets.

Mumbai / London / Rome / Zug: Lupin’s completion of the acquisition of VISUfarma marks a strategically important step in the company’s effort to build a stronger specialty-care presence outside its traditional core markets. Announced on 2 April 2026, the transaction brings VISUfarma, a European specialty pharmaceutical company focused on ophthalmology, into Lupin’s portfolio and significantly enhances the Indian drugmaker’s position in branded eye-care products across Europe. The acquisition is not merely a scale-driven transaction; it reflects a deliberate move toward higher-value therapeutic segments where branded expertise, physician relationships and market access capabilities can create longer-term competitive advantage.

Through this deal, Lupin expands its ophthalmology portfolio to more than 60 branded products covering dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and specialty nutraceuticals. Just as importantly, the acquisition brings with it a well-established commercial infrastructure across Italy, the United Kingdom, Spain, Germany and France. For Lupin, this broadens both its product reach and its ability to engage more deeply with ophthalmologists and specialty-care channels across Europe. At a time when pharmaceutical companies are increasingly prioritising focused specialty segments over volume-led commoditised businesses, VISUfarma offers Lupin a platform that is differentiated, regionally established and aligned with rising demand for advanced eye-care solutions.

The timing of the deal is also commercially relevant. Demand for ophthalmology products is being supported by structural healthcare trends, including ageing populations, increasing screen exposure, better diagnosis rates and a growing burden of diabetes-related eye conditions. In this context, Lupin’s investment in a specialised European eye-care business appears well judged. Rather than entering the market organically and building distribution relationships from scratch, Lupin has acquired an operating business with existing market knowledge, local commercial expertise and recognised product positions. This should help shorten execution timelines and reduce market-entry friction, while giving the company a stronger foundation for future expansion in specialty pharmaceuticals.

According to Vinita Gupta, CEO of Lupin, “the acquisition is a significant milestone because it adds a differentiated and innovation-led eye-health portfolio backed by an existing commercial infrastructure”. She also underscored that the transaction should accelerate the development of Lupin’s specialty franchise in Europe. Paolo Cioccetti, CEO Italy at VISUfarma, said that “Lupin’s international capabilities, long-term vision and commitment to ophthalmology make it a suitable strategic owner for the next stage of VISUfarma’s growth.”